Molecular diagnostics company Biodesix, Inc. is teaming up with clinical cancer genomics company Inivata to develop Next Generation Sequencing (NGS)-blood based tests for lung cancer.
The companies announced their partnership to develop and commercialize these tests for clinical applications in lung cancer, leveraging Inivata’s proprietary, enhanced Tam-Seq technology platform and Biodesix’ development and commercialization capabilities in the US market to provide new, clinically actionable tests to physicians.
“Approximately 30% of NSCLC patients are unable to obtain a biopsy or have insufficient tissue from a lung cancer biopsy to provide the diagnostic information for their cancer. Blood-based diagnostics can make a real difference in such cases. Using Inivata’s circulating tumor DNA (ctNDA) analysis platform, we can now provide information that was previously unattainable for these patients, leading to better outcomes,” said Michael Stocum, CEO of Inivata.
Financial terms of the agreement were not disclosed.
Under the deal, the companies will conduct studies in non-small cell lung cancer (NSCLC) using Inivata’s NGS technology platform. The studies will be jointly funded by Biodesix and Inivata to establish clinical utility for an NGS-based test. According to the companies, an observational study will be initiated later this year.
“The combination of our world-class blood-based sequencing technology with Biodesix’ ability to develop and establish diagnostics as standard of care creates a strong platform to develop new highly clinically relevant tests. We are excited to be working with Biodesix to improve the care offered to cancer patients,” said Inivata CSO Nitzan Rosenfeld.
Lung cancer is the leading cause of cancer death worldwide. Biodesix has already developed a clinically validated serum test for advanced NSCLC that helps physicians determine if a patient should receive treatment with Tarceva (erlotinib). The test requires a simple blood draw and can be performed on all advanced NSCLC patients. Test results are returned in less than 72 hours, allowing physicians to make a quick decision on treatment.
“Along with VeriStrat, a serum protein test that is already commercially available to help physicians guide treatment decisions for patients with advanced NSCLC, the blood-based NGS tests we’re developing with Inivata will further drive towards precision medicine by guiding diagnosis, prognosis and monitoring for patients with NSCLC,” said Biodesix CEO David Brunel.
Source: Biodesix, Inc.
Last updated: 3/11/15; 1:40pm EST